How to buy Sonoma Pharmaceuticals stock (SNOA)

Sonoma Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Sonoma Pharmaceuticals shares (SNOA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.63 – a decrease of 1.5% over the previous week. Sonoma Pharmaceuticals employs 10 staff and has a trailing 12-month revenue of around $12.7 million.

Our top picks for where to buy Sonoma Pharmaceuticals stock

Buy Sonoma Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sonoma Pharmaceuticals stock price (NASDAQ: SNOA)

Use our graph to track the performance of SNOA stocks over time.

Sonoma Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$2.63
52-week range	$2.44 - $9.37
50-day moving average more info button	$2.84
200-day moving average more info button	$3.80
Wall St. target price	$19.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.99

Is it a good time to buy Sonoma Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sonoma Pharmaceuticals price performance over time

Historical closes compared with the close of $2.55 from 2024-12-19

1 week (2024-12-13)	-4.49%
1 month (2024-11-21)	-12.37%
3 months (2024-09-20)	-26.30%
6 months (2024-06-21)	1,164.25%

1 year (2023-12-21)	1,556.92%
2 years (2022-12-21)	-88.72%
3 years (2021-12-21)	96
5 years (2019-12-20)	80.4

Sonoma Pharmaceuticals financials

Revenue TTM	$12.7 million
Gross profit TTM	$4.5 million
Return on assets TTM	-19.59%
Return on equity TTM	-74.65%
Profit margin	-35.91%
Book value	$7.86
Market Capitalization more info button	$3.4 million

TTM: trailing 12 months

Sonoma Pharmaceuticals share dividends

We're not expecting Sonoma Pharmaceuticals to pay a dividend over the next 12 months.

Have Sonoma Pharmaceuticals's shares ever split?

Sonoma Pharmaceuticals's shares were split on a 1:20 basis on 29 August 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonoma Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Sonoma Pharmaceuticals shares which in turn could have impacted Sonoma Pharmaceuticals's share price.

Sonoma Pharmaceuticals share price volatility

Over the last 12 months, Sonoma Pharmaceuticals's shares have ranged in value from as little as $2.44 up to $9.374. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonoma Pharmaceuticals's is 1.378. This would suggest that Sonoma Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sonoma Pharmaceuticals overview

Sonoma Pharmaceuticals, Inc. , develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Sonoma Pharmaceuticals is owned by insiders or institutions?
Currently 1.508% of Sonoma Pharmaceuticals shares are held by insiders and 2.416% by institutions. How many people work for Sonoma Pharmaceuticals?
Latest data suggests 10 work at Sonoma Pharmaceuticals. When does the fiscal year end for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals's fiscal year ends in March. Where is Sonoma Pharmaceuticals based?
Sonoma Pharmaceuticals's address is: 5445 Conestoga Court, Boulder, CO, United States, 80301 What is Sonoma Pharmaceuticals's ISIN number?
Sonoma Pharmaceuticals's international securities identification number is: US83558L2043 What is Sonoma Pharmaceuticals's CUSIP number?
Sonoma Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 67575P108